Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.74 |
| ▸ | PIM1 | P11309 | 10/20 | 0.74 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704232 | 1.00 | PIM2 (0.74) | PIM2PIM1FLT3PIM3PTPN1 | |
| SCHEMBL10091728 | 0.81 | PIM1 (0.59) | PIM2PIM1FLT3PIM3PTPN1 | |
| SCHEMBL703105 | 0.80 | PIM1 (0.61) | PIM2PIM1FLT3PIM3PTPN1 | |
| SCHEMBL703106 | 0.80 | PIM1 (0.61) | PIM2PIM1FLT3PIM3PTPN1 | |
| SCHEMBL12990442 | 0.80 | PIM2 (0.48) | PIM2PIM1FLT3PIM3MEN1 | |
| SCHEMBL700876 | 0.80 | PIM1 (0.62) | PIM2PIM1FLT3PIM3PTPN1 | |
| SCHEMBL12990281 | 0.79 | PIK3CG (0.48) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL3367020 | 0.79 | PIK3CG (0.48) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL3367012 | 0.79 | PIK3CG (0.48) | PIM2PIM1CSNK2A2CSNK2A1 | |
| SCHEMBL700877 | 0.79 | PIM1 (0.62) | PIM2PIM1FLT3PIM3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307421-A1 | OXINDOLE COMPOUNDS | Cylene Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM2 3/4885PIM1 2/4885FLT3 1/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM2 3/4885PIM1 2/4885FLT3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.